Fred Hutchinson Cancer Research Center Initiates Studies on ImmuneRegen BioSciences' Cancer Therapy Candidate
10 Febbraio 2010 - 2:00PM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced the
execution of an agreement with Fred Hutchinson Cancer Research
Center to commence studies utilizing ImmuneRegen's Homspera. Under
the agreement the Hutchinson Center will perform exploratory
studies on Homspera, specifically focusing on the area of cancer
immunotherapy. The Center expects to raise approximately $30
million within the next 3-4 years to support immunotherapy research
projects and has recently announced a gift of approximately
one-third of that amount. Studies at the Hutchinson Center will be
performed under the direction of Dr. Cassian Yee , who has
successfully used immune cells from patients with melanoma to cause
long-term remission in their tumors.
Recent studies have found Homspera to be effective in enhancing
the efficacy of a novel cancer vaccine, and previous studies have
revealed anti-tumor effects. These experiments taking place at the
Hutchinson Center are designed to expand on this previous research,
which has identified a critical role for Homspera in directing the
immune system towards fighting cancers -- in particular, aggressive
cancers where conventional therapies are ineffective. This work
will evaluate the effect of Homspera exposure on patients' own
cancer-specific cytotoxic T-cell stimulation. While these initial
studies will evaluate melanoma immunotherapy this model also has
clinical relevance for a wide-range of cancer types.
"We are excited to be pursuing this relationship, which offers
ImmuneRegen the opportunity to have Homspera further evaluated in
the area of melanoma by a group with enormous proven expertise.
Additionally, following successful findings, we would be situated
perfectly to leverage our relationship with research and clinical
experts at this leading Cancer Research Center who have experience
in developing therapies that translate to real world cancer
treatments. This could lead to a more rapid developmental path for
Homspera as well," said Hal Siegel, Ph.D., ImmuneRegen's Chief
Scientific Officer.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera®. Homspera is an adult
stem cell active compound that in study results has been shown to
regenerate and strengthen the immune system and enhance wound
healing. Homspera is being developed for potential use against
infectious diseases as a stand-alone or combination therapy and as
a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona
based company has forged numerous study partnerships with industry
and academic leaders, including Celgene Cellular Therapeutics,
HemoGenix, Lovelace Respiratory Research Institute and Virion
Systems. For more information, please visit
www.immuneregen.com.
Statements about the Company's future expectations, including
statements about the potential use and scientific results for the
Company's drug candidates, science and technology, and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. These future events may not occur as and when expected, if
at all, and, together with the Company's business, are subject to
various risks and uncertainties. The Company's actual results could
differ materially from expected results as a result of a number of
factors, including the uncertainties inherent in research and
development collaborations, pre-clinical and clinical trials and
product development programs (including, but not limited to the
fact that future results or research and development efforts may
prove less encouraging than current results or cause side effects
not observed in current pre-clinical trials), the evaluation of
potential opportunities, the level of corporate expenditures and
monies available for further studies, capital market conditions,
and others set forth in the Company's periodic report on Form 10-Q
for the three months ended September 30, 2009 as filed with the
Securities and Exchange Commission and report on Form 10-K for the
year ended December 31, 2008 as filed with the Securities and
Exchange Commission. There are no guarantees that any of the
Company's proposed products will prove to be commercially
successful. The Company undertakes no duty to update
forward-looking statements.
Contact: Michael K. Wilhelm email: Email Contact John
Fermanis email: Email Contact ImmuneRegen BioSciences Inc. Phone:
480-922-3926
Grafico Azioni IR BioSciences (CE) (USOTC:IRBS)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni IR BioSciences (CE) (USOTC:IRBS)
Storico
Da Ott 2023 a Ott 2024